Onset of significant GH dependence of serum IGF-I and IGF-binding protein 3 concentrations in early life

L C Low1, S Y Tam, E Y Kwan

  • 1Department of Paediatrics, The University of Hong Kong, Hong Kong SAR, PR China. lcklow@hkucc.hku.hk

Pediatric Research
|December 1, 2001
PubMed

Insights

The childhood growth phase begins around 6-10 months, marked by rising insulin-like growth factor-I (IGF-I) and growth hormone (GH) action. This study links early IGF-I and GH changes to infant length gain.

Area of Science:

  • Pediatric Endocrinology
  • Growth and Development
  • Human Physiology

Background:

  • Infant growth is regulated by complex hormonal interactions.
  • Insulin-like growth factor-I (IGF-I) and growth hormone (GH) are key regulators of postnatal growth.
  • The transition from infancy to childhood growth phases is not fully understood.

Purpose of the Study:

  • To investigate the relationship between serum GH-binding protein, IGF-I, and IGF-binding protein 3 levels and anthropometric measurements in infants.
  • To determine the timing of the onset of the childhood phase of growth.
  • To explore the association between hormonal changes and growth velocity during early development.

Main Methods:

  • Longitudinal study of 48 healthy Chinese infants from birth to 2 years.
  • Regular anthropometric measurements (length, BMI).
  • Serial blood sampling for GH-binding protein, IGF-I, and IGF-binding protein 3 analysis at birth, 6, 10, 12, and 18 months.

Main Results:

  • Serum GH-binding protein increased significantly by 6 months, while IGF-I and IGF-binding protein 3 rose from 10 months.
  • Early IGF-I changes (birth to 6 months) correlated with length and BMI gain.
  • Infants with earlier onset of childhood growth (6-10 months) showed higher IGF-I and length velocity compared to those with later onset.

Conclusions:

  • The onset of the childhood growth phase is associated with significant GH action.
  • Changes in GH-binding protein and IGF-I concentrations between 6 and 12 months, along with growth phase onset, predict length gain.
  • This study supports the hypothesis that GH action is crucial for initiating childhood growth.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...